AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii

被引：72

作者：

Ruzin, A ^{[1
]}

Keeney, D ^{[1
]}

Bradford, PA ^{[1
]}

机构：

[1] Wyeth Res, Dept Infect Dis, Pearl River, NY 10965 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 02期

关键词：

D O I：

10.1128/AAC.49.2.791-793.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Transposon mutagenesis of a clinical isolate of Morganella morganii, G1492 (tigecycline MIC of 4 mug/ml), yielded two insertion knockout mutants for which tigecycline MICs were 0.03 mug/ml. Transposon insertions mapped to acrA, which is constitutively overexpressed in G1492, suggesting a role of the AcrAB efflux pump in decreased susceptibility to tigecycline in M. morganii.

引用

收藏

页码：791 / 793

页数：3

相关论文

共 14 条

[1] In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].

Boucher, HW ;

Wennersten, CB ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229

[2] mar Operon involved in multidrug resistance of Enterobacter aerogenes [J].

Chollet, R ;

Bollet, C ;

Chevalier, J ;

Malléa, M ;

Pagès, JM ;

Davin-Regli, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1093-1097

[3] New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors [J].

Chopra, I .

DRUG RESISTANCE UPDATES, 2002, 5 (3-4) :119-125

[4] Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 [J].

Dean, CR ;

Visalli, MA ;

Projan, SJ ;

Sum, PE ;

Bradford, PA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :972-978

[5] Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae [J].

Linde, HJ ;

Notka, F ;

Irtenkauf, C ;

Decker, J ;

Wild, J ;

Niller, HH ;

Heisig, P ;

Lehn, N .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (04) :625-630

[6] Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli [J].

Oethinger, M ;

Podglajen, I ;

Kern, WV ;

Levy, SB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2089-2094

[7] In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) [J].

Petersen, PJ ;

Jacobus, NV ;

Weiss, WJ ;

Sum, PE ;

Testa, RT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :738-744

[8] In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens [J].

Petersen, PJ ;

Bradford, PA ;

Weiss, WJ ;

Murphy, TM ;

Sum, PE ;

Projan, SJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2595-2601

[9]

RUZIN A, IN PRESS ANTIMICROB

[10]

Sambrook J., 2002, MOL CLONING LAB MANU